There are 2949 resources available
832P - GEICO1601-ROLANDO trial: A multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
Presenter: Jose Alejandro Perez Fidalgo
Session: E-Poster Display
Resources:
Abstract
833P - Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and bevacizumab (BEV): Final results from a study in patients (pts) with recurrent platinum sensitive ovarian cancer
Presenter: David O'Malley
Session: E-Poster Display
Resources:
Abstract
834P - A phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear-cell carcinoma (KCOG-G1601 trial)
Presenter: Kimihiko Ito
Session: E-Poster Display
Resources:
Abstract
835P - Clinical outcomes of advanced/ recurrent ovarian clear cell carcinoma in a multi-ethnic Asian cohort following bevacizumab and immune checkpoint inhibitor therapy
Presenter: Natalie Ngoi
Session: E-Poster Display
Resources:
Abstract
836P - Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
Presenter: Erika Hamilton
Session: E-Poster Display
Resources:
Abstract
837P - Phase II trial of oncolytic vaccinia virus primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC) (NCT02759588)
Presenter: Robert Holloway
Session: E-Poster Display
Resources:
Abstract
839P - A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer
Presenter: Erika Hamilton
Session: E-Poster Display
Resources:
Abstract
838P - TRIOC-A randomised phase II trial to examine MVA-5T4 vaccine in patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
Presenter: Agnieszka Michael
Session: E-Poster Display
Resources:
Abstract
840P - Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study
Presenter: Lingfang Xia
Session: E-Poster Display
Resources:
Abstract
841P - Phase II study of anlotinib plus pemetrexed for platinum-resistant epithelial ovarian cancer
Presenter: Jueming Chen
Session: E-Poster Display
Resources:
Abstract